M Gabriela Barbaglia, Javier Molero-Calafell, Ariadna Angulo-Brunet, Saül Alcaraz, Montse Bartroli, Joan I Mestre-Pintó
{"title":"Association of Lifetime Psychiatric Comorbidity and Current Substance Use in Methadone-Treated Individuals with Opioid Use Disorders.","authors":"M Gabriela Barbaglia, Javier Molero-Calafell, Ariadna Angulo-Brunet, Saül Alcaraz, Montse Bartroli, Joan I Mestre-Pintó","doi":"10.1080/15504263.2025.2557191","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The primary objective of this study was to assess the association between psychiatric comorbidity and current substance use in a sample of patients with opioid use disorder (OUD) receiving opioid agonist treatment (OAT) with methadone in outpatient drug treatment centers. Secondary objectives were: (a) to examine the associations between socio-demographic and clinical characteristics and specific substance use (opioids, cocaine, alcohol, cannabis), and (b) to identify the socio-demographic and clinical factors associated with substance use based on lifetime psychiatric comorbidity status.</p><p><strong>Methods: </strong>A convenience sample of 588 patients (20% women; <i>M</i><sub>age</sub> 48.4) was recruited from eight outpatient drug treatment centers in Catalonia (Spain), which offer a comprehensive treatment approach. Dual diagnosis was assessed using the Dual Disorder Screening Interview (DDSI), and self-reported substance use (opioids, cocaine, cannabis, and alcohol) was evaluated through a specific questionnaire. Poisson regression with a log link was used to test five models adjusted for sociodemographic, clinical, and treatment variables.</p><p><strong>Results: </strong>A total of 63.5% of the patients tested positive for a lifetime dual diagnosis, and 83.5% reported substance use in the past month. No increased likelihood of opioid, cocaine, or alcohol use was observed among those with a lifetime dual diagnosis, except for cannabis use (<i>PR</i> = 1.29).</p><p><strong>Conclusions: </strong>Psychiatric comorbidity was not associated with current substance use in methadone-treated patients, except cannabis use. The observed patterns may be influenced by the pharmacological effects of methadone and the comprehensive treatment approach provided to patients.</p>","PeriodicalId":46571,"journal":{"name":"Journal of Dual Diagnosis","volume":" ","pages":"1-13"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dual Diagnosis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15504263.2025.2557191","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The primary objective of this study was to assess the association between psychiatric comorbidity and current substance use in a sample of patients with opioid use disorder (OUD) receiving opioid agonist treatment (OAT) with methadone in outpatient drug treatment centers. Secondary objectives were: (a) to examine the associations between socio-demographic and clinical characteristics and specific substance use (opioids, cocaine, alcohol, cannabis), and (b) to identify the socio-demographic and clinical factors associated with substance use based on lifetime psychiatric comorbidity status.
Methods: A convenience sample of 588 patients (20% women; Mage 48.4) was recruited from eight outpatient drug treatment centers in Catalonia (Spain), which offer a comprehensive treatment approach. Dual diagnosis was assessed using the Dual Disorder Screening Interview (DDSI), and self-reported substance use (opioids, cocaine, cannabis, and alcohol) was evaluated through a specific questionnaire. Poisson regression with a log link was used to test five models adjusted for sociodemographic, clinical, and treatment variables.
Results: A total of 63.5% of the patients tested positive for a lifetime dual diagnosis, and 83.5% reported substance use in the past month. No increased likelihood of opioid, cocaine, or alcohol use was observed among those with a lifetime dual diagnosis, except for cannabis use (PR = 1.29).
Conclusions: Psychiatric comorbidity was not associated with current substance use in methadone-treated patients, except cannabis use. The observed patterns may be influenced by the pharmacological effects of methadone and the comprehensive treatment approach provided to patients.
期刊介绍：
Journal of Dual Diagnosis is a quarterly, international publication that focuses on the full spectrum of complexities regarding dual diagnosis. The co-occurrence of mental health and substance use disorders, or “dual diagnosis,” is one of the quintessential issues in behavioral health. Why do such high rates of co-occurrence exist? What does it tell us about risk profiles? How do these linked disorders affect people, their families, and the communities in which they live? What are the natural paths to recovery? What specific treatments are most helpful and how can new ones be developed? How can we enhance the implementation of evidence-based practices at clinical, administrative, and policy levels? How can we help clients to learn active recovery skills and adopt needed supports, clinicians to master new interventions, programs to implement effective services, and communities to foster healthy adjustment? The Journal addresses each of these perplexing challenges.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
